Paraoxonase Activity and Antibodies to Oxidized-LDL in Chronic Renal Failure Patients on Renal Replacement Therapy

Overview

Journal Indian J Clin Biochem

Specialty Biochemistry

Date 2012 Oct 30

PMID 23105639

Citations 4

Authors

P R Krishnaswamy

Anjali Rao

W Murali

H Sudarshan Ballal

Affiliations

Soon will be listed here.

Abstract

Serum paraoxonase (PON1) and antibodies to oxidized-LDL (anti ox-LDL) were measured in chronic renal failure subjects on renal replacement therapy such as hemodialysis (HD) peritoneal dialysis (PD) and transplantation (Txp). Paraoxonase activity was significantly lower in HD and PD group (P<0.001) than in control subjects. In transplant patients, paraoxonase activity was not significantly different from that of controls. Antibodies to ox-LDL was significantly higher in HD, PD and Transplant patients (P<0.0001) compared to control subjects. High titers of antibodies were observed in the HD group compared to the PD and Transplant subjects. A decrease in paraoxonase activity and high titers of Antibodies to ox-LDL in the dialysis group suggest a decreased cardio protective effect of HDL and enhanced risk of premature cardiovascular complications. Whereas in case of transplant subjects, there seems to be restoration of PON1 activity, but elevated levels of anti-oxLDL could still be a potential atherogenic factor. Hence, we propose that estimation of these two parameters can be used as a useful index to measure the cardiac risk in the above patient category.

Citing Articles

Paraoxonase 1 Activity and Renal Replacement Therapy for Chronic Renal Failure: A Meta-Analysis.

Watanabe J, Kotani K, Iwazu Y, Gugliucci A J Clin Med. 2023; 12(15).

PMID: 37568524 PMC: 10419928. DOI: 10.3390/jcm12155123.

Novel oxidized LDL-based clinical markers in peritoneal dialysis patients for atherosclerosis risk assessment.

Papadea P, Kalaitzopoulou E, Skipitari M, Varemmenou A, Papasotiriou M, Papachristou E Redox Biol. 2023; 64:102762.

PMID: 37302344 PMC: 10363433. DOI: 10.1016/j.redox.2023.102762.

Association between moderately oxidized low-density lipoprotein and high-density lipoprotein particle subclass distribution in hemodialyzed and post-renal transplant patients.

Kimak E, Halabis M, Baranowicz-Gaszczyk I, Solski J, Ksiazek A J Zhejiang Univ Sci B. 2011; 12(5):365-71.

PMID: 21528490 PMC: 3087092. DOI: 10.1631/jzus.B1000348.

Paraoxonase: Its antiatherogenic role in chronic renal failure.

Prakash M, Phani N, Kavya R, Supriya M Indian J Nephrol. 2010; 20(1):9-14.

PMID: 20535264 PMC: 2878404. DOI: 10.4103/0971-4065.62088.

References

Cristol J, Canaud B, Rabesandratana H, Gaillard I, Serre A, Mion C . Enhancement of reactive oxygen species production and cell surface markers expression due to haemodialysis. Nephrol Dial Transplant. 1994; 9(4):389-94. View

Paul J, Sall N, Soni T, Poignet J, LINDENBAUM A, Man N . Lipid peroxidation abnormalities in hemodialyzed patients. Nephron. 1993; 64(1):106-9. DOI: 10.1159/000187287. View

Wang C, Salahudeen A . Lipid peroxidation accompanies cyclosporine nephrotoxicity: effects of vitamin E. Kidney Int. 1995; 47(3):927-34. DOI: 10.1038/ki.1995.138. View

Mackness M, Abbott C, Arrol S, Durrington P . The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J. 1993; 294 ( Pt 3):829-34. PMC: 1134536. DOI: 10.1042/bj2940829. View

Dantoine T, DeBord J, Charmes J, Merle L, Marquet P, Lachatre G . Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol. 1998; 9(11):2082-8. DOI: 10.1681/ASN.V9112082. View

Inselmann G, Blank M, Baumann K . Cyclosporine A induced lipid peroxidation in microsomes and effect on active and passive glucose transport by brush border membrane vesicles of rat kidney. Res Commun Chem Pathol Pharmacol. 1988; 62(2):207-20. View

Paragh G, Asztalos L, Seres I, Balogh Z, Locsey L, Karpati I . Serum paraoxonase activity changes in uremic and kidney-transplanted patients. Nephron. 1999; 83(2):126-31. DOI: 10.1159/000045489. View

Chait A, Brazg R, Tribble D, Krauss R . Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med. 1993; 94(4):350-6. DOI: 10.1016/0002-9343(93)90144-e. View

Haagen L, Brock A . A new automated method for phenotyping arylesterase (EC 3.1.1.2) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clin Biochem. 1992; 30(7):391-5. DOI: 10.1515/cclm.1992.30.7.391. View

10.

Esterbauer H, Gebicki J, Puhl H, Jurgens G . The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med. 1992; 13(4):341-90. DOI: 10.1016/0891-5849(92)90181-f. View

11.

Himmelfarb J, Lazarus J, Hakim R . Reactive oxygen species production by monocytes and polymorphonuclear leukocytes during dialysis. Am J Kidney Dis. 1991; 17(3):271-6. DOI: 10.1016/s0272-6386(12)80473-2. View

12.

Witztum J, Steinberg D . Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991; 88(6):1785-92. PMC: 295745. DOI: 10.1172/JCI115499. View

13.

Serino F, Grevel J, Napoli K, Kahan B, Strobel H . Oxygen radical formation by the cytochrome P450 system as a cellular mechanism for cyclosporine toxicity. Transplant Proc. 1994; 26(5):2916-7. View

14.

Cristol J, Maggi M, Vela C, Descomps B, Mourad G . Lipid metabolism and oxidative stress in renal transplantation: implications for chronic rejection. Transplant Proc. 1996; 28(5):2820-1. View

15.

Odetti P, Garibaldi S, GURRERI G, Aragno I, Dapino D, Pronzato M . Protein oxidation in hemodialysis and kidney transplantation. Metabolism. 1996; 45(11):1319-22. DOI: 10.1016/s0026-0495(96)90108-0. View

16.

Watson A, Berliner J, Hama S, La Du B, Faull K, Fogelman A . Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 1995; 96(6):2882-91. PMC: 185999. DOI: 10.1172/JCI118359. View

17.

Schiavon R, De Fanti E, Giavarina D, Biasioli S, Cavalcanti G, Guidi G . Serum paraoxonase activity is decreased in uremic patients. Clin Chim Acta. 1996; 247(1-2):71-80. DOI: 10.1016/0009-8981(95)06221-1. View

18.

Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier C . Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med. 1999; 26(7-8):892-904. DOI: 10.1016/s0891-5849(98)00272-x. View

19.

Mackness M, Arrol S, Durrington P . Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 1991; 286(1-2):152-4. DOI: 10.1016/0014-5793(91)80962-3. View

20.

Steinberg D, Parthasarathy S, Carew T, Khoo J, Witztum J . Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989; 320(14):915-24. DOI: 10.1056/NEJM198904063201407. View